Skip to content

Kailera Therapeutics

US · KLRA #3073 by market cap Listed 2026
11.02 -0.56 -4.84%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Revenue annual, last 2 years

Income statement

Line item 2024 2025
Revenue ----
Gross profit ----
Selling & admin expenses --49.23M
Research & development --109.11M
Operating profit ---158.34M
Pretax profit ---148.96M
Tax ----
Net profit ---148.96M
Basic EPS ---1
Diluted EPS ---1.26

Balance sheet

Line item 2024 2025
Total current assets 177.61M557.54M
Cash & ST investments 175.18M546.06M
Inventory ----
Total assets 178.45M692.29M
Total current liabilities 6.91M46.41M
Short-term debt 509.00K1.04M
Long-term debt ----
Total liabilities 397,217,000.001,048,752,000.00
Total equity -218.77M-356.46M
Retained earnings -219.71M-368.67M

Cash flow

Line item 2024 2025
Operating cash flow ---120.21M
Depreciation & amortization --310.00K
Free cash flow ---122.30M
Dividends paid ----
Stock buybacks / issuance ----
Ending cash balance --161.03M

Returns & efficiency

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Kailera Therapeutics discussion 0 comments

Add a comment